The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer
- PMID: 41449156
- DOI: 10.1016/S1470-2045(25)00601-1
The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer
Conflict of interest statement
JPN declares grants from Heidelberger Stiftung Chirurgie, Dietmar Hopp Stiftung GmbH, Bundesministerium für Bildung und Forschung, and Stiftung Deutsche Krebshilfe; holds a patent from Metavert; and sits on the BioNTech Advisory Board on BNT321. CS sits on advisory boards for AstraZeneca, Bayer, BMS, Incyte, Servier, Taiho, and Revolution Medicine; has received support for attending meetings from Servier; and received payment for lectures from Roche. All other authors declare no competing interests.
Publication types
LinkOut - more resources
Full Text Sources
